LYEL 8-K 2026-11-04
Lyell Immunopharma, Inc. (LYEL) 8-K dated 2026-11-04 — accession 0001628280-26-070161.
Lyell Immunopharma, Inc. (LYEL) is a biotechnology company listed on US.
LYEL revenue $3000
This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.
Latest reported LYEL revenue for 2025-12-31 was $36.0K. Net income was -$274.4M. Revenue was down 41.0% from 2024-12-31 to 2025-12-31. LYEL currently screens at market cap $143.5M.
Not investment advice. The LYEL SEC hub lists recent forms. The stock page is the research view.
- Revenue
- $3000
- Guidance
- guidance presented in accordance with GAAP, we present non-GAAP net loss, non-GAAP R&D expenses and non-GAAP G&A expenses. Non‑G
Why it matters
- guidance presented in accordance with GAAP, we present non-GAAP net loss, non-GAAP R&D expenses and non-GAAP G&A expenses. Non‑G
- The updated ronde-cel data accepted for presentation at ASH further strengthen our conviction in ronde-cel’s potential to meaningfully improve outcomes for p…